Evidence map›Paper›PMID 33802220›Full record

ArticleInternational journal of molecular sciences2021

Metabolic Glycoengineering in hMSC-TERT as a Model for Skeletal Precursors by Using Modified Azide/Alkyne Monosaccharides.

Stephan Altmann, Jürgen Mut, Natalia Wolf, Jutta Meißner-Weigl, Maximilian Rudert, Franz Jakob, Marcus Gutmann, Tessa Lühmann, Jürgen Seibel, Regina Ebert

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Beyond labeling: differential AcRegenerative biomaterials · 2026
    Article
  4. Aluminum-[EJNMMI radiopharmacy and chemistry · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. The Applications of Metabolic Glycoengineering.Frontiers in cell and developmental biology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Stephan AltmannBernhard-Heine-Center for Locomotion Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.
Jürgen MutInstitute of Organic Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Natalia WolfInstitute of Organic Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Jutta Meißner-WeiglBernhard-Heine-Center for Locomotion Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.
Maximilian RudertBernhard-Heine-Center for Locomotion Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.
Franz JakobBernhard-Heine-Center for Locomotion Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.
Marcus GutmannInstitute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.ORCID 0000-0001-6000-7923
Tessa LühmannInstitute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Jürgen SeibelInstitute of Organic Chemistry, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Regina EbertBernhard-Heine-Center for Locomotion Research, University of Würzburg, Friedrich-Bergius-Ring 15, 97076 Würzburg, Germany.ORCID 0000-0002-8192-869X
University of Würzburg · DE

Funding

Deutsche Forschungsgemeinschaft Project number 326998133 - TRR 225 (subproject B05)
6 · The paper itself

Abstract

Metabolic glycoengineering enables a directed modification of cell surfaces by introducing target molecules to surface proteins displaying new features. Biochemical pathways involving glycans differ in dependence on the cell type; therefore, this technique should be tailored for the best results. We characterized metabolic glycoengineering in telomerase-immortalized human mesenchymal stromal cells (hMSC-TERT) as a model for primary hMSC, to investigate its applicability in TERT-modified cell lines. The metabolic incorporation of

Indexed as

GlycocalyxHexosaminesMetabolic EngineeringModels, BiologicalCell Line, TransformedHumansMesenchymal Stem CellsMyoblasts, Skeletal2-acetamido-1,3,4,6-tetra-O-acetyl-2-deoxymannopyranoseHexosaminesclick chemistryglycocalyxhMSC-TERTmetabolic glycoengineeringmodified monosaccharides

Identifiers

PMID33802220
PMCPMC7999278
OpenAlexW3133525178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.